Zymeworks

$25.62
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.42 (-1.61%) Today
$0.00 (0.00%) As of 4:02 PM EDT after-hours

Why Robinhood?

You can buy or sell Zymeworks and other stocks, options, ETFs, and crypto commission-free!

About ZYME

Zymeworks Inc., also called Zymeworks, is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. Read More The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.

Employees
183
Headquarters
Vancouver, British Columbia
Founded
2003
Market Cap
822.99M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
404.37K
High Today
$26.07
Low Today
$25.44
Open Price
$26.05
Volume
306.19K
52 Week High
$29.75
52 Week Low
$10.72

Collections

ZYME Earnings

-$0.83
-$0.13
$0.58
$1.28
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 5, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.